ClinicalTrials.gg
RecruitingNCT05178693LANTanaUpdated Nov 12, 2026

Lutathera and ASTX727 in Neuroendocrine Tumours

A Phase 1 interventional study of ASTX727 and Lutathera in Neuroendocrine Tumors, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Imperial College London · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 6 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies in Neuroendocrine Tumors with a site in United Kingdom — 4 open to participants now, 9 under way, 5 of them phase 3. Neuroendocrine Tumors · United Kingdom.

Planned enrollment
25th of 31
37 · median 97
Started
2022
the only one that year
Phase 1
3 of 38
1 open now
Registered
33rd of 38
by date
Lead sponsor
4 of 38
Imperial College London

Among the 38 studies in Neuroendocrine Tumors with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 1, and was the 33rd registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

4 of the 38 studies in Neuroendocrine Tumors with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Neuroendocrine Tumors with a site in United Kingdom, or all of them as a file.
02

Study summary

Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus.

Read the detailed description

Patients with neuroendocrine tumours (NET) who are found to be eligible will receive up to 4 doses of Lutathera on this trial. All participants will receive ASTX727 orally (cedazuridine 100mg + 35mg decitabine) Days 0-5 prior to receiving Lutathera Day 8 +/- 2days. Each cycle will be repeated every 2 months for 4 cycles unless unacceptable toxicity, progression of disease or withdrawal of patients' consent. Restaging will occur after 2 cycles of Lutathera and at the end of treatment. Patients will be followed 3 monthly until disease progression, death or withdrawal of patients' consent.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to provide written for the trial.
  2. Be aged 18 or over at the day of signing consent
  3. Histologic or cytologic confirmed diagnosis of neuroendocrine tumour
  4. Have block available or willing to have fresh tissue biopsy if blocks not available
  5. Have disease that can be readily biopsied by ultrasound guidance (n=5)
  6. Ki67 \< 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months)
  7. Progression or intolerance to therapy including somatostatin analogues
  8. Performance status 0 - 2
  9. No tumoural uptake on [68Ga]-DOTA-TATE or uptake less than background liver
  10. based on 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  11. Adequate organ function as outlined in the protocol
  12. Women of must be willing to use a highly effective method of as outlined in the protocol for the course of the study through 6 months after the last dose of Medicinal Product (IMP).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects

  13. Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

    Expansion Cohort (n=10 participants):

  14. \<50% disease occupation of liver

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with either study medication and/or known to the study medication
  2. Serious concurrent medical illness, including serious active infection
  3. History of organ transplant
  4. Has a known history of (HIV). Note: No HIV testing is required unless mandated by local health authority.
  5. Has a known history of active Bacillus Tuberculosis (TB).
  6. Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to first dose of study treatment.
  7. Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage
  8. Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an device within 4 weeks of the first dose of IMP.
  9. Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  12. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP.
  13. Has received a within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  14. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
  15. Other co-morbidities that could compromise the subject's participating in the study

Expansion Cohort (n=10 participants):

15. > 2 lines of previous therapy, excluding somatostatin analogues

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Treatment

    Drug: ASTX727 · Radiation: Lutathera

  • Other
    Expansion Cohort

    Drug: ASTX727 · Radiation: Lutathera

Interventions

  • DrugASTX727

    Cedazuridine 100mg + 35mg decitabine

  • RadiationLutathera

    Peptide receptor radionuclide therapy (PRRT)

    Also known as: lutetium Lu 177 dotatate

06

What researchers measure

Primary outcomes

  1. To determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using [68Ga]-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera

    This outcome will be assessed using a specific PET scan

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. To assess tolerability of combination therapy

    This outcome will be assessed using CTCAE v5.0

    Time frame: Through study completion, an average of 1 year

  2. To assess response to treatment using conventional imaging

    This outcome will be assessed using standard of care CT scans

    Time frame: Through study completion, an average of 1 year

  3. To assess patients quality of life during treatment

    This will be assessed using standardised quality of life questionnaires, which will be given to the patients

    Time frame: Through study completion, an average of 1 year

  4. To assess progression free survival

    This will be the time until patients show progressive disease on their routine CT scans

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Murphy R, Chander G, Martinez M, Ward C, Khan SR, Naik M, Barwick T, Aboagye E, Sharma R. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. BMJ Open. 2023 Oct 24;13(10):e075221. doi: 10.1136/bmjopen-2023-075221. PubMed 37879695 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for May 2027, 61 months after the start.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 61 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → May 2027 and completion Feb 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Jan 5, 2022
StartActual
Apr 25, 2022
Primary completionEst.
May 30, 2027was Jun 2026
CompletionEst.
Jan 30, 2030was Feb 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→May 30, 2027
Nov 12, 2026
Study completion
Feb 28, 2029→Jan 30, 2030
Nov 12, 2026
Enrollment
27→37
Nov 12, 2026
Eligibility
2 inclusion criteria added; 2 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedExpansion Cohort (n=10 participants):
  • Added<50% disease occupation of liver
Exclusion criteria
  • AddedExpansion Cohort (n=10 participants):
  • Added15. > 2 lines of previous therapy, excluding somatostatin analogues
Nov 12, 2026
Interventions
Arms added: Expansion Cohort
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 30, 2026→May 30, 2027
    Study completion Feb 28, 2029→Jan 30, 2030
    Enrollment 27→37
    Eligibility 2 inclusion criteria added; 2 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedExpansion Cohort (n=10 participants):
    • Added<50% disease occupation of liver
    Exclusion criteria
    • AddedExpansion Cohort (n=10 participants):
    • Added15. > 2 lines of previous therapy, excluding somatostatin analogues
    Interventions Arms added: Expansion Cohort
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05178693
Responsible party
Sponsor
First posted
Jan 5, 2022
Start date
Apr 25, 2022
Primary completion
May 30, 2027 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Rohini Sharma, Professor
Contact
rohini.sharma2@nhs.net
02083833170
Rohini Sharma, Professor
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion